文献速递药物不良反应与药物警戒

因果推断工具在药物警戒中的应用:使用因果图识别和解决不一致性分析中的偏倚

Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality Analysis.
PubMed 文献 · Drug Saf · 2025-12-11

不一致性分析广泛用于药物警戒,但固有偏倚和数据特征常使关联偏离因果。该文提出基于有向无环图(DAG)的因果框架,系统记录并解决不一致性分析中的偏倚(如混杂、对撞、测量和报告偏倚),并以FDA不良事件报告系统案例展示其应用,使用信息成分作为不一致性指标、限制作为条件。DAG可优化设计、提高透明度和信号可靠性,但需谨慎使用,不能提供因果问题的确定性答案。

要点

  • DAG可系统识别并解决不一致性分析中的混杂、对撞、测量和报告偏倚。
  • 使用DAG优化不一致性分析设计,可提高灵敏度和特异度及透明度。
  • DAG有助于缩小关联与因果之间的差距,但不可提供确定性因果结论。

核心结论

  • 使用DAG映射和减轻偏倚需谨慎,不能获得因果问题的确定性答案。
  • 但仍可产生更可靠和基于知识的安全信号,缩小发现(关联)与寻找(因果)之间的差距。

研究设计与样本

  • 方法学文章,提出基于DAG的因果框架,并应用于FDA不良事件报告系统案例研究。
  • 使用信息成分作为不一致性指标,使用限制作为条件。

主要发现

  • DAG促进现有知识和因果假设的形式化,优化不一致性分析设计以减轻偏倚,从而提高灵敏度和特异度。
  • DAG改善透明度,更好地形成批评,突出不一致性分析的局限性,并指导后续研究解决残余混杂和更广泛的证据合成。

关键数值与推荐

  • 不一致性分析中需系统记录和解决的偏倚包括混杂、对撞、测量和报告偏倚。
  • 案例研究使用信息成分作为不一致性指标。

临床怎么用

  • 临床药学智能体可参考DAG框架在解读不一致性分析结果时系统评估偏倚。
  • 利用DAG指导后续研究设计以解决残余混杂。

局限性

  • 使用DAG映射和减轻偏倚需要谨慎,不能提供因果问题的确定性答案。
  • 需要进一步研究定制DAG以适应药物警戒挑战、映射药物警戒数据的生成机制,并更好地将不一致性分析结果整合到证据合成工作流程中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Disproportionality analysis, finding associations in the co-reporting of drugs and events, is widely used in pharmacovigilance to detect potential safety signals of adverse drug reactions. However, inherent biases and unique data features often cause disproportionality to diverge from causation, and a comprehensive framework to address these issues is lacking. OBJECTIVE: We showcase how directed acyclic graphs (DAGs) can enhance disproportionality analysis-related inferences, better qualifying its limitations and catalysing its inclusion in the broader evidence landscape. METHODS: We introduce a DAG-based causal framework to systematically document and address biases in disproportionality analyses (e.g., confounding, colliders, measurement and reporting biases). We illustrate its application to case studies from the Food & Drug Administration (FDA) Adverse Event Reporting System-using the Information Component as a disproportionality metric and restriction as conditioning. RESULTS: Directed acyclic graphs facilitate the formalisation of existing knowledge and causal assumptions, optimise the design of disproportionality analysis to mitigate biases-thereby enhancing sensitivity and specificity-improve transparency, better enable the formulation of critiques, highlight limitations of disproportionality and guide follow-up studies to address residual confounding and broader evidence synthesis. CONCLUSION: Using DAGs to map and mitigate biases requires caution and does not allow to obtain definitive answers to causal questions. Still, it results in more reliable and knowledge-based safety signals, reducing and mapping the gap between what we find (association) and what we look for (causation). Additional research should further tailor DAGs to pharmacovigilance challenges, map the generative mechanisms of pharmacovigilance data, and better integrate disproportionality analysis results into evidence-synthesis workflows.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Fusaroli M, Mitchell J, Rudolph A, et al. Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality Analysis. Drug Saf. 2025. PMID: 41381798. doi:10.1007/s40264-025-01628-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。